The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).
 
Michael J. Overman
Consulting or Advisory Role - 3D Medicines; Array BioPharma; Bristol-Myers Squibb; Eisai; Gritstone Bio; Janssen; Janssen; MedImmune; Merck; Novartis; Pfizer; Pfizer; Promega; Roche/Genentech; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Greg Yothers
Employment - Mountainview Pediatrics (I)
Consulting or Advisory Role - Orbus Therapeutics
 
Samuel A. Jacobs
Employment - Exact Sciences
Consulting or Advisory Role - Exact Sciences
 
Hanna Kelly Sanoff
Research Funding - Amgen (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst)
 
Deirdre Jill Cohen
Consulting or Advisory Role - Astellas Pharma; Taiho Oncology
Speakers' Bureau - Guardant Health
Research Funding - Eisai (Inst); Merck (Inst); Viome
 
Katherine A Guthrie
No Relationships to Disclose
 
Norah Lynn Henry
Consulting or Advisory Role - Myovant Sciences
Research Funding - Blue Note Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalty from Up-to-Date
 
Patricia A. Ganz
Leadership - Intrinsic LifeSciences (I)
Stock and Other Ownership Interests - Abbott Laboratories; GlaxoSmithKline; Intrinsic LifeSciences (I); Johnson & Johnson; Merck; Novartis; Pfizer; Silarus Therapeutics (I); Teva; xenon pharma (I)
Consulting or Advisory Role - Akebia Therapeutics (I); Ambys Medicines (I); American Regent (I); Astellas Pharma (I); Blue Note Therapeutics; Disc Medicine (I); GlaxoSmithKline (I); Global Blood Therapeutics (I); Gossamer Bio (I); Grail; InformedDNA; Ionis Pharmaceuticals (I); Protagonist Therapeutics (I); Regeneron (I); Rockwell Medical Technologies Inc (I); Sierra Oncology (I); Vifor Pharma (I)
Research Funding - Blue Note Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - related to iron metabolism and the anemia of chronic disease (I); Up-to-Date royalties for section editor on survivorship
Travel, Accommodations, Expenses - Intrinsic LifeSciences (I)
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Iylon; Lutris; Navire; Xilis
Consulting or Advisory Role - Abbvie; Accademia Nazionale Di Medicina (ACCMED); Amal Therapeutics; Amgen; AstraZeneca/MedImmune; Bayer Health; Bicara Therapeutics; Black Diamond Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Cardiff Oncology; Carina Biotech; CureTeq; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Foundation Medicine; Frontier Medicines; Genentech; Genomic Health; Gilead Sciences; GlaxoSmithKline; HalioDx; Harbinger Oncology, Inc; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Lutris; Merck; Mirati Therapeutics; NeoGenomics Laboratories; Novartis; Numab; Ono Pharmaceutical; Pfizer; Redx Pharma; Repare Therapeutics; Replimune; Servier; Taiho Pharmaceutical; Takeda; Tempus; Xilis; Zentalis
Research Funding - Amgen; Array BioPharma; Biocartis; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; MedImmune; Novartis; Sanofi
 
Peter C. Lucas
Stock and Other Ownership Interests - Amgen
Honoraria - Schrodinger (I)
Patents, Royalties, Other Intellectual Property - Patent No PCT/US2022/021720, "Small molecules and their use as MALT1 inhibitors"
 
Charles David Blanke
No Relationships to Disclose
 
Theodore S. Hong
Stock and Other Ownership Interests - PanTher Therapeutics
Consulting or Advisory Role - Boston Scientific; Merck; Novocure; Syndax; Synthetic Biologics
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb (Inst); IntraOp (Inst); Ipsen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst)
 
Norman Wolmark
Research Funding - Genentech (Inst)
 
Howard S. Hochster
Stock and Other Ownership Interests - Compass Therapeutics; Processa Pharmaceuticals
Consulting or Advisory Role - Bayer; Genentech; Merck
Speakers' Bureau - Natera
 
Thomas J. George
Consulting or Advisory Role - Pfizer; Tempus
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); OncoC4 (Inst); Seagen (Inst)
 
Caio Max Sao Pedro Rocha Lima
Research Funding - Boston Biomedical; Pharmacyclics; Rafael Pharmaceuticals